Soterix Medical Inc.
Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation.
Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.
Soterix Medical was founded to support the science of non-invasive electrical stimulation. Our stimulation systems are the only technology designed and optimized for advanced and reliable neuromodulation. From exclusive High-Definition systems, Neurotargeting planning software, to the incredibly adaptable 1×1 platform, researchers choose Soterix Medical when stimulation quality cannot be compromised.
Soterix Medical is committed to provide patients and physicians the most advanced, user-friendly, and effective neuromodulation treatments. Our clinical tDCS platforms are the only system to incorporate the latest, most robust technology. Unique electrode and head-gear snap-in technology make consistent and comfortable stimulation “a snap” for patient and care-givers.